Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 3Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Gastrointestinal Stromal Tumors 6Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Neoplasms 2Neoplasm Metastasis 2Melanoma 2Sarcoma 1Relapsed Pediatric Solid Tumor 1Mesothelioma 1Meningioma 1Leukemia, Myeloid 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1GIST 1Drug-Related Side Effects and Adverse Reactions 1Chordoma 1Central Nervous System Neoplasms 1Carcinoma, Adenoid Cystic 1Brain Neoplasms 1

Interventions

Immunotherapy, Adoptive 2flumatinib 1fludarabine 1Thiotepa 1Sensitivity and Specificity 1Imatinib Mesylate 1Idarubicin 1Diagnosis 1Deferasirox 1Decitabine 1Daunorubicin 1Cytarabine 1Cladribine 1Busulfan 1Blood Specimen Collection 1Azacitidine 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Myeloid × Imatinib Mesylate × Clear all
NCT01503502 2013-04-10

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
150 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡